The primary objective is to evaluate taste preferences for alcohol during an intravenous infusion of the naturally occurring hormone fibroblast growth factor-21 (FGF21) and placebo (i.e. saline), respectively, in 20 healthy subjects. Secondary endpoints are to evaluate the effects of exogenous FGF21 (compared to placebo) on resting energy expenditure, preference for salt, sour and bitter taste qualities, sensations of hunger, thirst, appetite, satiety, headache and nausea, and makers of glucose metabolism (e.g. plasma/serum concentrations of glucose, C-peptide, insulin and glucagon).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Enrollment
20
Infusion of Fibroblast growth factor 21
Infusion of Saline
Amalie R Lanng
Hellerup, Denmark
Alcohol preference (How much do you want to drink alcohol?)
Evaluated by Visual analogue scale from "not at all" to "more than ever"
Time frame: 1 year
Plasma glucose concentration
Plasma glucose concentration
Time frame: 1 year
Serum insulin concentration
Serum insulin concentration
Time frame: 1 year
Plasma fibroblast growth factor-21 concentration
Plasma fibroblast growth factor-21 concentration
Time frame: 1 year
Serum C-peptide concentration
Serum C-peptide concentration
Time frame: 1 year
Plasma glucagon concentration
Serum C-peptide concentration
Time frame: 1 year
Plasma lipid profile
Plasma concentrations of triglycerides, total cholesterol, free fatty acids
Time frame: 1 year
Plasma insulin-like growth factor 1 concentration
Plasma insulin-like growth factor 1 concentration
Time frame: 1 year
Plasma bone marker concentration
Plasma concentrations of the bone markers carboxy-terminal collagen crosslink and procollagen type 1 N-terminal propeptide
Time frame: 1 year
Resting energy expenditure
Evaluated by indirect calorimetry
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.